Avian Influenza

Carrington comments on bird flu pandemic, provides update on DelSite vaccine

Published in Health Business Week, February 16th, 2007

In view of a recent article in the January 16, 2007 Wall Street Journal about a "Permanent Threat" regarding the risk of an H5N1 (bird flu) pandemic and recent incidence of human cases in Vietnam and China, Carrington Laboratories, Inc., (CARN) issued a status report on DelSite Biotechnologies, Inc.'s influenza vaccine development.

DelSite, a wholly-owned subsidiary of Carrington, has been developing a platform for the development of a vaccine for an H5N1 flu pandemic with funding from the National Institute of Allergy and Infectious Disease, Department of Human Health Services (NIAID, DHHS). GelVac is the platform for nasal powder delivery of preservative-free...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week

Source: Health Business Week (2007-02-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry